GCM
RNAC icon

Graham Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Graham Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-442
Closed -$8.63K – 1316
2024
Q1 		$8.63K Sell
442
-84
-16% -$1.78K ﹤0.01% 1027
2023
Q4 		$10.9K Buy
+526
New +$15.7K ﹤0.01% 960

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Graham Capital Management's RNAC Position: Q2 2024 in Review

Graham Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 442 shares — an estimated $8.63K sold.

Graham Capital Management first reported a position in RNAC in Q4 2023 and held it in 2 quarters. The position peaked at $10.9K in Q4 2023. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Graham Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Graham Capital Management sold 442 Cartesian Therapeutics shares in Q2 2024, an estimated $8.63K.
  • Graham Capital Management first reported a position in Cartesian Therapeutics in Q4 2023 and held it in 2 quarters.
  • Graham Capital Management's Cartesian Therapeutics position peaked at $10.9K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.